Grabenbauer G G, Löhnert C, Erhardt J, Buchfelder M, Neubauer U, Beck J D, Reitz S, Seyer H, Thierauf P, Fietkau R
Strahlentherapeutische Klinik, Universität Erlangen-Nürnberg.
Strahlenther Onkol. 1993 Apr;169(4):213-21.
Between 1975 and 1991, 40 patients with newly diagnosed medulloblastoma were treated at the authors' institutions. After aggressive surgical resection 39/40 (98%) received craniospinal radiation therapy with a local boost to the posterior fossa and other macroscopically involved areas. A group of 29 patients was treated with adjuvant chemotherapy. The five-year actuarial survival and event-free survival were 75% and 65%, respectively. Survival was significantly better for patients treated after 1981 as compared to those treated between 1975 and 1980 (p = .02). Younger age (two to four years) was associated with a better prognosis (p = .02). The extend of resection, Chang-stage, radiation dose to posterior fossa and the use of chemotherapy did not significantly impact on survival and relapse-free survival.
1975年至1991年间,作者所在机构对40例新诊断的髓母细胞瘤患者进行了治疗。在积极的手术切除后,40例中有39例(98%)接受了颅脊髓放射治疗,并对后颅窝和其他肉眼可见受累区域进行局部加量照射。一组29例患者接受了辅助化疗。5年精算生存率和无事件生存率分别为75%和65%。与1975年至1980年间接受治疗的患者相比,1981年后接受治疗的患者生存率显著更高(p = 0.02)。年龄较小(2至4岁)与较好的预后相关(p = 0.02)。切除范围、Chang分期、后颅窝放射剂量以及化疗的使用对生存率和无复发生存率没有显著影响。